Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Human Renal Cell Carcinoma (RCC) Cell Lines Derived from Surgically Removed Tumors

Posted Dec 01 2009 4:00pm

Description of Invention:
Scientists at the National Institutes of Health (NIH) have developed three cell lines obtained from renal cell carcinoma (RCC) patients. The cell lines, designated 1581 RCC, 1764 RCC, and 2194 RCC, were derived from human tumor samples surgically resected from patients in the inventors' clinic. Each cell line is human leukocyte antigen-A2 (HLA-A2) negative and expresses a variety of known tumor antigens. The 1764 RCC cell line is known to express the HLA-A3 antigen and high levels of nonmutated fibroblast growth factor 5 (FGF-5). These cell lines can be widely used in molecular biology for various assays and to screen for potential therapeutics with activity against RCC. The RCC cell lines can also serve as negative control samples for HLA-A2 expression.

Applications:
  • Research tools for examining the common and diverse biological and pathological features of RCC from different patients in vitro
  • Research tools for testing the activity of potential anti-cancer drugs against RCC
  • Source for mRNA and protein antigens expressed in kidney cancer
  • Negative control cell lines for HLA-A2 expression in molecular biology
  • Possible starting material for developing a cancer vaccine against RCC


Advantages:
  • Cell lines are derived directly from RCC patient samples: These cell lines are anticipated to retain many features of primary RCC samples. Studies performed using these cell lines may have a direct correlation to the initiation, progression, treatment, and prevention of RCC in humans.
  • Do not express the HLA-A2 allele: A majority of the cancer vaccines and immunotherapies developed to date have focused on utilizing HLA-A2 restricted tumor epitopes since this HLA allele is largely expressed in the human population. However, therapies restricted to HLA-A2 recognition will not be successful in RCC patients that do not express this allele. For these RCC patients, additional therapies are needed that are directed against epitopes presented by different HLA alleles.


Inventors:
Kenichi Hanada (NCI)
Qiong J Wang (NCI)
James C Yang (NCI)


Patent Status:
HHS, Reference No. E-005-2010/0

Research Tool -- patent protection is not being pursued for this technology

Relevant Publication:
  1. K Hanada et al. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001 Jul 15;61(14):5511-5516. [ PubMed abs ]


Licensing Status:
Available for licensing under a Biological Materials License Agreement.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Research Materials



For Additional Information Please Contact:
Samuel Bish Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: bishse@mail.nih.gov
Phone: 301-435-5282
Fax: 301-402-0220


Ref No: 2044

Updated: 12/2009

Post a comment
Write a comment: